Identification of the minimum non-inferior dose in a three-arm non-inferiority trial

被引:0
作者
Zhong, Junjiang [1 ]
Wen, Miin-Jye [2 ,3 ]
Cheung, Siu Hung [4 ,5 ]
机构
[1] Xiamen Univ Technol, Sch Appl Math, Xiamen, Peoples R China
[2] Natl Cheng Kung Univ, Inst Data Sci, Dept Stat, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Inst Int Management, Tainan, Taiwan
[4] Chinese Univ Hong Kong, Dept Stat, Hong Kong, Peoples R China
[5] Southern Univ Sci & Technol, Dept Stat & Data Sci, Shenzhen, Peoples R China
关键词
Assay sensitivity; Familywise error rate; Minimum non-inferior dose; Test power; Three-arm non-inferiority trial; MULTIPLE TEST PROCEDURES; DOUBLE-BLIND; PEPTIDE-1; ANALOG; GLYCEMIC CONTROL; METFORMIN; GLIMEPIRIDE; EFFICACY; PLACEBO; SAFETY; LIRAGLUTIDE;
D O I
10.1007/s42952-020-00053-w
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
Non-inferiority (NI) trials have gained recognition as an effective tool with which to search for substitutes for a standard treatment that is associated with certain undesirable features, such as adverse side-effects, an exorbitant cost, or an extremely complicated therapeutic regimen. Statistical methods have been developed for NI studies with multiple experimental treatments. However, experimental treatments sometimes represent a new treatment with various dose levels, and in such circumstances, identification of the minimum non-inferior dose is a reasonable objective of the trial. Thus, we examine several potential testing procedures with respect to this testing objective. A simulation study is conducted to evaluate their performance, and determination of the sample size is discussed. Two clinical examples are provided to illustrate the proposed method.
引用
收藏
页码:1238 / 1254
页数:17
相关论文
共 36 条
  • [1] [Anonymous], 2005, Doc. Ref. EMEA/CPMP/EWP/2158/99
  • [2] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
    Bachelez, Herve
    van de Kerkhof, Peter C. M.
    Strohal, Robert
    Kubanov, Alexey
    Valenzuela, Fernando
    Lee, Joo-Heung
    Yakusevich, Vladimir
    Chimenti, Sergio
    Papacharalambous, Jocelyne
    Proulx, James
    Gupta, Pankaj
    Tan, Huaming
    Tawadrous, Margaret
    Valdez, Hernan
    Wolk, Robert
    [J]. LANCET, 2015, 386 (9993) : 552 - 561
  • [3] Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma
    Beeh, K. M.
    Derom, E.
    Kanniess, F.
    Cameron, R.
    Higgins, M.
    van As, A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) : 871 - 878
  • [4] Issues in the assessment of non-inferiority: perspectives drawn from case studies
    Burger, H. Ulrich
    Beyer, Ulrich
    Abt, Andmarkus
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (05) : 433 - 439
  • [5] Emerging inhaled bronchodilators: an update
    Cazzola, M.
    Matera, M. G.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (03) : 757 - 769
  • [6] Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease Indacaterol Versus Tiotropium
    Donohue, James F.
    Fogarty, Charles
    Lotvall, Jan
    Mahler, Donald A.
    Worth, Heinrich
    Yorgancioglu, Arzu
    Iqbal, Amir
    Swales, James
    Owen, Roger
    Higgins, Mark
    Kramer, Benjamin
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (02) : 155 - 162
  • [8] A STEP-UP MULTIPLE TEST PROCEDURE
    DUNNETT, CW
    TAMHANE, AC
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1992, 87 (417) : 162 - 170
  • [9] Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases
    Ellenberg, SS
    Temple, R
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) : 464 - 470
  • [10] Issues in Noninferiority Trials: The Evidence in Community-Acquired Pneumonia
    Fleming, Thomas R.
    Powers, John H.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 : S108 - S120